#125: The MS Brain Health Strategy: Treatments, Cognitive Tools & Patient Empowerment with Prof. Barbara Willekens
In this episode, we dive into the topic of brain health in multiple sclerosis—what it really means, why it matters, and how you can actively support it in your daily life. Neurologist Prof. Barbara Willekens shares practical strategies around early treatment, healthy routines, cognitive function, and the role of digital tools. We also explore how […]
#124: Multiple Sclerosis Clinical Trials – Discover the Benefits, Ease the Worries
Today, we’re diving into a topic that sparks interest for many – but is often accompanied by uncertainty or hesitation: clinical trials. For people living with chronic, immune-mediated conditions like Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), or MOG Antibody Disease (MOGAD), clinical trials can represent hope – hope for new treatment options, improved […]
#111: Pregnancy, childbirth, and breastfeeding with multiple sclerosis—my personal experiences
In der heutigen Podcastfolge geht es um Schwangerschaft, Geburt, geburtstvorbereitungskurs und Stillen mit Multipler Sklerose (MS).
#091: New treatment strategies in MS an ECTRIMS Special
This time, I will present some studies on new treatment options for MS that show promising results and were presented at ECTRIMS 2024. Some candidates are not that new, such as high-dose vitamin D, but the key here is the long-term observation of a large number of MS patients under clearly defined conditions. Furthermore, there […]
#083: ECTRIMS Special on De-escalation and discontinuation of therapies for MS – What does it mean and how can it work?
Hello and welcome to another summary of ECTRIMS 2024, this time on the topic of de-escalation and discontinuation of therapy. There was a scientific session on this topic with six lectures, moderated by Dr. Melinda Magyari and Prof. Bernhard Hemmer. And there were also individual posters. Except for one talk about NMOSD and MOGAD, all […]
#080: B-Cell Depletion – Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Rituximab (Mabthera, Rituxan), Ublituximab (Briumvi) for active RRMS and SPMS, and early PPMS
Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
#078: Cladribine (Mavenclad, Leustat, Litak) for highly active MS
Cladribine (Mavenclad, Leustat, Litak) is an induction therapy the supresses the immun system and is used for highly active MS.
#076: Alemtuzumab (Lemtrada, Campath) for highly active Multiple Sclerosis
Alemtuzumab (Lemtrada, Campath) is a DMT to treat highly active MS and has long-lasting effects and potential severe side effects.
#074: S1P Modulators – Fingolimod (Gilenya), Ozanimod (Zeposia), Ponesimod (Ponvory), Siponimod (Mayzent) for active RRMS & SPMS
Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
#072: Natalizumab (Tysabri, Tyruko) for active relapsing remitting MS
Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
